These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30224383)

  • 1. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.
    Neumann U; Ufer M; Jacobson LH; Rouzade-Dominguez ML; Huledal G; Kolly C; Lüönd RM; Machauer R; Veenstra SJ; Hurth K; Rueeger H; Tintelnot-Blomley M; Staufenbiel M; Shimshek DR; Perrot L; Frieauff W; Dubost V; Schiller H; Vogg B; Beltz K; Avrameas A; Kretz S; Pezous N; Rondeau JM; Beckmann N; Hartmann A; Vormfelde S; David OJ; Galli B; Ramos R; Graf A; Lopez Lopez C
    EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.
    Machauer R; Lueoend R; Hurth K; Veenstra SJ; Rueeger H; Voegtle M; Tintelnot-Blomley M; Rondeau JM; Jacobson LH; Laue G; Beltz K; Neumann U
    J Med Chem; 2021 Oct; 64(20):15262-15279. PubMed ID: 34648711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease.
    Liu CG; Wang JL; Li L; Wang PC
    Int J Mol Med; 2014 Jul; 34(1):160-6. PubMed ID: 24827165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo.
    Kim ML; Zhang B; Mills IP; Milla ME; Brunden KR; Lee VM
    J Neurosci; 2008 Nov; 28(46):12052-61. PubMed ID: 19005070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
    Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
    Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects.
    Neumann U; Machauer R; Shimshek DR
    Br J Pharmacol; 2019 Sep; 176(18):3435-3446. PubMed ID: 30657591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
    Jacobsen H; Ozmen L; Caruso A; Narquizian R; Hilpert H; Jacobsen B; Terwel D; Tanghe A; Bohrmann B
    J Neurosci; 2014 Aug; 34(35):11621-30. PubMed ID: 25164658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance.
    Singh N; Das B; Zhou J; Hu X; Yan R
    Sci Adv; 2022 Jul; 8(29):eabo3610. PubMed ID: 35857844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
    Imbimbo BP; Watling M
    Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
    [No Abstract]   [Full Text] [Related]  

  • 12. The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease.
    Lopez Lopez C; Caputo A; Liu F; Riviere ME; Rouzade-Dominguez ML; Thomas RG; Langbaum JB; Lenz R; Reiman EM; Graf A; Tariot PN
    J Prev Alzheimers Dis; 2017; 4(4):242-246. PubMed ID: 29181489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage.
    Netzer WJ; Bettayeb K; Sinha SC; Flajolet M; Greengard P; Bustos V
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1389-1394. PubMed ID: 28115709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.
    Paris D; Ganey NJ; Laporte V; Patel NS; Beaulieu-Abdelahad D; Bachmeier C; March A; Ait-Ghezala G; Mullan MJ
    J Neuroinflammation; 2010 Mar; 7():17. PubMed ID: 20211007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission.
    Satir TM; Agholme L; Karlsson A; Karlsson M; Karila P; Illes S; Bergström P; Zetterberg H
    Alzheimers Res Ther; 2020 May; 12(1):63. PubMed ID: 32456694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology.
    Mohajeri MH; Saini KD; Nitsch RM
    J Neural Transm (Vienna); 2004 Mar; 111(3):413-25. PubMed ID: 14991462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.
    Timmers M; Barão S; Van Broeck B; Tesseur I; Slemmon J; De Waepenaert K; Bogert J; Shaw LM; Engelborghs S; Moechars D; Mercken M; Van Nueten L; Tritsmans L; de Strooper B; Streffer JR
    J Alzheimers Dis; 2017; 56(4):1437-1449. PubMed ID: 28157093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.
    Jeppsson F; Eketjäll S; Janson J; Karlström S; Gustavsson S; Olsson LL; Radesäter AC; Ploeger B; Cebers G; Kolmodin K; Swahn BM; von Berg S; Bueters T; Fälting J
    J Biol Chem; 2012 Nov; 287(49):41245-57. PubMed ID: 23048024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
    Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
    Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.